Exec-Edge, Author at ExecEdge - Page 14 of 143

Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease

Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s Disease. The nomination comes after the company exercised its option with JCR Pharmaceuticals as part...

Enhanced Raises $50M to Fuel Next Phase, Backed by Major Investors

Enhanced Raises $50M to Fuel Next Phase, Backed by Major Investors

By Karen Roman Enhanced Group Inc. (NYSE: ENHA) said it closed a $50 million private investment in public equity financing. The transaction was led by Apeiron Investment Group, Enhanced co-founder and Chairman’s Christian Angermayer family office, as well as co-Founder...

Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates

Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates

By Karen Roman Imviva Biotech said it is presenting two findings associated with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at the European Hematology Association 2026 Congress taking place on June 11-14, 2026, in Stockholm, Sweden. The global TENACITY-01 study...

Input your search keywords and press Enter.